SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is experiencing volatility, with community members noting a lack of clear news catalysts for recent price swings. Despite broader market rallies, $TTD struggles to hold gains, leading to frustration among investors and speculation about market manipulation. Some investors point to a potential inverse head and shoulders pattern and analyst price target reiterations as positives, while others highlight the company's upcoming earnings release and potential benefits from shifts in the ad tech landscape.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc ($UUUU) is experiencing significant price volatility, driven by unusual options activity and discussions around its strategic positioning in the uranium and rare earth elements sectors. Community members are actively debating whether recent price movements are due to manipulation, insider trading, or broader market corrections, with some highlighting the company's potential to benefit from government contracts and the shift towards domestic resource independence. The stock's price action is also being influenced by news of a joint venture in Australia and increased investment in the company.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to FDA approval of its leukemia drug Revuforj, although a black box warning about potentially fatal side effects has tempered enthusiasm. The community is debating the significance of the safety label, with some seeing a buying opportunity while others express concern. Despite the approval, the stock has declined, prompting discussion about short selling, market manipulation, and potential future buyout offers.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as retail investors rally behind a potential short squeeze, fueled by high borrowing costs and a perceived scarcity of shares available for shorting. The community is actively discussing strategies to pressure short sellers, with some pointing to insider buying as a bullish signal. Despite some volatility, there's a general sentiment that a significant move is on the horizon, and that high CTB/borrowing fees are making it hard for shorts to maintain positions.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending as traders discuss a potential short squeeze and a low float, with some drawing comparisons to other stocks that have experienced significant upward movement. The community is actively watching key breakout levels, anticipating a rapid price increase if certain thresholds are met. However, concerns remain around reverse splits and the company's financials.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

PMI is trending as traders react to a recent price drop, with some citing a company statement addressing the decline and others pointing to a potential misunderstanding of a recent SEC filing regarding share dilution. The community is actively debating whether the stock represents a long-term value opportunity, while also questioning if the volatility is related to a pump-and-dump scheme. Some traders are reporting difficulty buying shares on certain platforms, further fueling speculation.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is gaining attention due to recent news of insider buying and a milestone payment from Merck, sparking discussions about its low float and potential for a short squeeze. The community is actively analyzing the stock's setup, watching for a breakout, with some eyeing a potential run toward double digits. However, the possibility of a near term offering is also being discussed.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Shares of ADMA are experiencing volatility, with community members pointing to potential manipulation and profit-taking as possible causes for recent price swings. While some investors express concern over open put positions and overall market conditions, others are optimistic about a pre-earnings run-up, citing strong pre-market activity and anticipating positive earnings driven by a new FDA-approved production process. Some are also speculating about a potential buyout, while others suggest the recent slide provides a buying opportunity given the company's fundamentals.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze its potential ahead of upcoming earnings, with community members closely watching for guidance updates and AI-related catalysts. Discussions include the stock's recent trading patterns, support levels, and potential breakout points, with some suggesting a possible earnings run-up. Additionally, Microsoft's partnerships and positioning in the AI infrastructure space remain a key focus for many traders.

MaxsMaking, Inc. is a holding company, which engages in the manufacture of customized consumer goods. It offers a range of customizable textile products, including backpacks, thermal bags, canvas bags, aprons, throw pillows, flags, and advertising chair covers. The company was founded by Xiao Zhong Lin and Xue Fen Zhang in January 2007 and is headquartered in Shanghai, China.

MaxsMaking Inc. - Ordinary Shares - Class A

MaxsMaking Inc. Class A Ordinary Shares

MaxsMaking Inc. is trending due to discussions around its low float and potential for significant price movement, with some traders drawing comparisons to other stocks that have experienced similar runs. The community is actively debating the stock's fundamentals, particularly its connection to the textile industry and manufacturing in China, while also noting the numerous trading halts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates

Avantor (AVTR) delivered earnings and revenue surprises of -4.00% and +0.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biodesix Inc’s shares jumped Wednesday, driven by a sizable insider purchase and heightened retail investor optimism, even as Scotiabank cut its price target to $2 from $3 after the company reported weaker-than-expected first-quarter (Q1) revenue.The stock surged 45.9% to close at $0.4 on Wednesday, before falling 11.4% in after-hours trading to $0.35.Biodesix’s first-quarter revenue reached $17.96 million, below the analysts' anticipated $19.5 million consensus estimate.The lowered target also reflects a downward revision of the full-year 2025 revenue guidance amid a strategic commercial shift.Biodesix revised its 2025 revenue guidance to $80 million–$85 million, down from earlier forecasts.&nbsp;The company posted Q1 2025 revenue growth of 21% year-over-year, with diagnostic testing revenue rising 18% and development services revenue surging 61%.&nbsp;Gross margins improved to 79.4%, and net loss narrowed by 18%.&nbsp;CEO Scott Hutton said that a commercial pilot in late 2024 expanded outreach to pulmonologists and primary care physicians managing roughly half of lung nodule patients.&nbsp;After the pilot’s success, Biodesix restructured its sales team into a territory-based model across multiple specialties, delaying commercial expansion by about one quarter and contributing to the revised guidance.Despite the revenue miss and guidance cut, Biodesix reiterated expectations to achieve adjusted EBITDA positivity by Q4 2025, supported by strong gross margins and cost efficiencies.&nbsp;Over the past month, multiple research firms have lowered their price targets on Biodesix amid a challenging outlook.&nbsp;Notably, Canaccord cut its target twice — from $3.50 to $2.50 and further down to $1.50 — citing tariffs, funding uncertainty, and below-expectation Q1 results.&nbsp;Other firms,&nbsp;such as Lake Street and TD Cowen, lowered their targets to $2 following a Q1 revenue miss and salesforce restructuring.Craig-Hallum dropped its target to $1.50, anticipating further sell-offs, and William Blair downgraded the stock to ‘Market Perform’ due to slower sales-representative hiring and higher attrition.Meanwhile, the company said Tuesday that Jack W. Schuler, a 10% owner and director, executed a purchase of 4.7 million shares on May 16 for $1.3 million.&nbsp;Schuler previously served as&nbsp;president and&nbsp;chief operating officer of Abbott Laboratories before joining Ventana.&nbsp;Currently, Schuler controls 35.9 million common shares, all held indirectly.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 510% surge in 24-hour message volume.One user urged investors to "trust the process" and maintain patience, citing Biodesix’s potential to meet compliance standards and reach profitability organically by year-end.&nbsp;<stembedurl>https://stocktwits.com/Trader1397/message/615454686</stembedurl>Meanwhile, others expressed optimism about Schuler’s recent sizable insider purchase, emphasizing his strong healthcare background and suggesting his stake could help spark renewed investor interest and upward momentum in the stock.<stembedurl>https://stocktwits.com/Babybillysbiblebonker/message/615448768</stembedurl>The stock has declined 73.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut

Investors cheered a 4.7 million share insider purchase and rallied behind the company’s push toward Q4 EBITDA positivity, offsetting Scotiabank’s price target cut to $2 after a Q1 revenue miss and lowered 2025 guidance.

Equity

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30...

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston...

Biodesix to Present at Two Investor Conferences in September

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team will present at two upcoming investor...

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on...

Biodesix Named to Inc. Magazines 2024 Best Workplaces

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazines Best Workplaces list. The ranking is a result of a comprehensive...

Biodesix to Participate in Two Investor Conferences in June

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor...

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.49	--	--	N/A
Q2 '25	-$0.07	-$1.60	-2216.59%	MISSED
Q1 '25	-$0.07	-$0.08	-14.64%	MISSED
Q4 '24	-$0.07	-$0.06	10.74%	BEAT
Q3 '24	-$0.07	-$0.07	4.28%	BEAT

BDSX
Biodesix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest BDSX News

BDSXBiodesix Inc